Health Care Equipment

Avinger

Avinger released FY2024 Q3 earnings on November 7 After-Market (EST), actual revenue $1.65M (forecast $1.635M), actual EPS -1.8232 (forecast -2.03)

Avinger released FY2024 9 Months Earnings on November 7 After-Market (EST), with actual revenue of 5,356,000 USD and EPS of -7.1259

Avinger to Release FY2024 Q3 Earnings on November 7 After-Market EST, Forecast Revenue 1.635 M USD, EPS -2.03 USD

Avinger expects quarterly revenue to grow by 25%

Avinger announces pricing of public offering

Avinger reduces staff by 33% in peripheral business

Avinger Inc received notice from Nasdaq

A SPAC III Acquisition

PicoCELA

ECD Automotive Design

Northann

Davis Commodities

Paranovus ENT Tech

Titan Mining

Bristol-Myers Squibb Company

Gauzy

Starfighters Space

Delcath

Electromed

Abbott Laboratories

Intuitive Surgical

Boston Scientific

Stryker

IDEXX Labs

Edwards Lifesciences

Resmed

DexCom

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap